Novel Start Trial

All Done!

A bit more to do?    Log in


The latest from the Spiral blog . . .

Coronavirus and how we play the adaptation game

2020-02-20
We are busy adapting one of our biggest projects to collect data and eventually provide feedback on the best treatment for the novel coronavirus outbreak COVID-19.
Coronavirus mutated( or adapted) recently to give us SARS-CoV-2 and the COVID-19 disease. Adaptation is a great skill for a virus – it's a pretty keen skill for people too, and we are using it to fight back against this disease ... read how »


 
 

Follow us on Twitter

     
 

Like us on Facebook




 

About the Novel START Study

The Novel START (Novel Symbicort Turbuhaler Asthma Reliever Therapy) study is a 52- week, open label, parallel group, multicentre, phase III, randomised controlled trial to compare the efficacy and safety of three asthma treatment regimens.

Participants will be recruited from sites in 9 regions in 4 countries (New Zealand, Australia, Italy and the United Kingdom).

About the software

Spinnaker is a tailored, web based, software and database solution for managing your multi-centre clinical study including the recording of patient data, recording and alerting of events, inventory management and reporting on data collected during the course of your study. Spinnaker is user friendly, adaptable and can be delivered quickly. You can read more on the Spinnaker website or contact Audrey on spinnaker@spiral.co.nz.

 

You can get to know us a little better through our blog and social media pages accessed via the logout screen of this trial.